Search

everythinglearnresearchcommunity

for

Search:↓

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Efalizumab can cause unexpected excessive hair growth.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

New treatments for lupus show promise, but more research is needed, especially for children.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Clofazimine effectively treated ashy dermatosis in a patient.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Leflunomide successfully treated a rare skin condition in a liver transplant patient.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.